What topics does this cannabis study cover?

This study covers research on: CBD, THC, Endocannabinoid, Mental Health.

Where was this research published?

Published in Der Nervenarzt on August 4, 2026.

CBD products promise benefits, but safety and quality remain concerns

Q: What did this Review find?

The review found **no robust evidence** for the health benefits commonly claimed for commercially available *CBD* products.

[Psychiatric aspects of commercially available products containing cannabidiol].

Der Nervenarzt • August 4, 2026 • Review • Highly Relevant

🤖

AI Summary

This selective literature review examines the benefits and risks of commercially available products containing CBD. Although CBD is generally described as well tolerated, the abstract lists possible side effects including elevated liver enzymes, sedation, reduced appetite, diarrhea, sleep disturbances, infections, and weight loss. It also notes that CBD is processed by several drug-metabolizing pathways, creating a potentially important but poorly studied risk of interactions with other medicines.

The review found no robust evidence supporting the health benefits commonly advertised for these products. It also reports that many products contain different amounts of CBD than their labels claim, and that THC is frequently detected. At doses of 4.3 mg/kg/day or more, there are indications of significant liver toxicity, while benefits claimed at or below that level are not supported by evidence. For consumers, the main message is that over-the-counter CBD products should not automatically be assumed to be accurately labeled or risk-free, particularly for people taking medications or with liver concerns.

💡 Key Findings

The review found no robust evidence for the health benefits commonly claimed for commercially available CBD products.

Good

75%

At oral doses of 4.3 mg/kg/day or more, the abstract reports indications of significant hepatotoxicity; possible side effects also include sedation, diarrhea, appetite loss, and elevated liver enzymes.

Good

70%

Many commercial products reportedly have substantial mismatches between labeled and actual CBD content, and THC was frequently detected.

Good

75%

CBD may have a theoretically high potential for pharmacokinetic drug interactions, although this risk has not been well studied.

Good

65%

📄 Original Abstract

Cannabidiol (CBD) has gained sustained public, medical, and scientific attention in recent years. The prevalence of use of commercially available products containing CBD (CPC) is correspondingly high. Overview of the benefits and risks of CPC, taking into account certain aspects related to CBD as a pharmaceutical active ingredient. Selective literature search in the PubMed database. Currently, only one primarily CBD-containing drug is approved in Germany (Epidyolex®). CBD demonstrates good safety and tolerability. Elevated transaminases, sedation, decreased appetite, diarrhea, sleep disturbances, infections, and weight loss are possible side effects. CBD modulates the endocannabinoid system and interacts with numerous other molecular targets. CBD is metabolized via CYP2C19, CYP3A4, and UGT. The potential for pharmacokinetic interactions with CBD has not been well studied, but is theoretically high. The potential for abuse of CBD is negligible when administered orally, but should be investigated more thoroughly for inhalation and higher-dose use. Studies have found significant discrepancies between the stated and actual CBD content in many CPC; THC was frequently detected. There is no evidence supporting the health benefits typically claimed by manufacturers for ≤ 4.3 mg of oral CBD/kg/day, but there are indications of significant hepatotoxicity at ≥ 4.3 mg of oralCBD/kg/day. There is no robust evidence of health benefits associated with CPC. However, given the levels of exposure, product deficiencies, and the EFSA safety concerns, it must be assumed that there are relevant health risks (particularly hepatotoxicity) associated with the use of CPC. HINTERGRUND: Cannabidiol (CBD) hat in den letzten Jahren anhaltende allgemeine sowie medizinische und wissenschaftliche Aufmerksamkeit erlangt. Die Konsumprävalenz von kommerziell erhältlichen CBD-haltige Präparaten (KCP) ist entsprechend hoch. Übersicht über Nutzen und Risiken von KCP unter Beachtung einiger Aspekte, die CBD als pharmazeutischen Wirkstoff betreffen. Selektive Literaturrecherche in der Datenbank PubMeb. Aktuell ist nur ein primär CBD-haltiges Medikament in Deutschland zugelassen (Epidyolex®). CBD weist eine gute Sicherheit und Verträglichkeit auf. Transaminasenerhöhungen, Sedierung, Appetitminderung, Diarrhoe, Schlafstörungen, Infektionen und Gewichtsverlust sind mögliche Nebenwirkungen. CBD moduliert das Endocannabinoidsystem und interagiert mit zahlreichen weiteren molekularen Zielen. CBD wird über CYP2C19, CYP3A4 und UGT metaboliert. Das pharmakokinetisches Interaktionspotential von CBD ist nicht gut untersucht, theoretisch aber groß. Das Missbrauchspotential von CBD ist bei oraler Anwendung vernachlässigbar, sollte jedoch bei inhalativer und höher dosierter Anwendung stärker geprüft werden. In Studien fand sich bei vielen KCP eine ausgeprägte Diskrepanz zwischen angegebenem und tatsächlichem CBD-Gehalt; häufig konnte THC nachgewiesen werden. Es gibt keine die herstellerseitig typischerweise behaupteten gesundheitsbezogenen Vorteile von ≤ 4,3 mg oralem CBD/kg/d unterstützende Evidenz, aber Hinweise auf relevante Hepatotoxizität bei ≥ 4,3 mg oralem CBD/kg/d. Es gibt keine belastbare Evidenz für gesundheitsbezogene Vorteile von KCP. Unter Beachtung erreichbarer Expositionen, der Produktmängel sowie der Sicherheitsbedenken der EFSA müssen jedoch relevante Gesundheitsrisiken (v. a. Hepatotoxizität) bei der Anwendung von KCP angenommen werden.